News & Views
At Enveda, we believe that cutting-edge technologies, evolution’s complexity, and a patient-driven purpose are a recipe for breakthroughs. Follow our journey as we learn, grow, and showcase our progress.
News & Publications
A Recursion veteran is mapping plant life to chart a course to new therapies — and investors like what they see
One of the earliest employees at AI biotech Recursion Pharmaceuticals is leading a new company, and he’s just closed a hefty Series A to get things moving. Enveda Biosciences pulled in $51 million in the raise, the company announced Tuesday morning, with the goal of pushing some of its preclinical programs further along.
One of the earliest employees at AI biotech Recursion Pharmaceuticals is leading a new company, and he’s just closed a hefty Series A to get things moving. Enveda Biosciences pulled in $51 million in the raise, the company announced Tuesday morning, with the goal of pushing some of its preclinical programs further along.
Lux Capital Leads $51 Million Financing in Biotech Startup Enveda - Company searches for compounds from nature to develop medications
Lux Capital has led a $51 million venture-capital financing in Enveda Biosciences Inc., a biotechnology startup led by an entrepreneur who previously helped build another successful life-sciences company in Lux’s portfolio.
Lux Capital has led a $51 million venture-capital financing in Enveda Biosciences Inc., a biotechnology startup led by an entrepreneur who previously helped build another successful life-sciences company in Lux’s portfolio.
Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital
BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, today announced an oversubscribed $51M Series A funding round. The financing was led by Lux Capital, with...
BOULDER, Colo.--(BUSINESS WIRE)--Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, today announced an oversubscribed $51M Series A funding round. The financing was led by Lux Capital, with...
Exploiting the Therapeutic Potential of Plants
Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges”....
Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges”....
Exclusive: Enveda Biosciences Announces $4.9M Seed To Create Medicinal Plant Database
Enveda Bioscienes has raised a seed round of $4.9 million to build what it touts to be the “world’s largest database of anthropological, chemical and biological data from medicinal plants.”...
Enveda Bioscienes has raised a seed round of $4.9 million to build what it touts to be the “world’s largest database of anthropological, chemical and biological data from medicinal plants.”...
Enveda Biosciences Systematically Harnesses Untapped Potential of Nature’s Chemistry to Develop Next-Gen Therapeutics
SAN FRANCISCO--(BUSINESS WIRE)--Enveda Biosciences today announced its seed round of funding in the amount of $4.9 million led by True Ventures, with participation from Wireframe Ventures, Village Global and angel investor Chris Gibson (co-founder and CEO of Recursion)....
SAN FRANCISCO--(BUSINESS WIRE)--Enveda Biosciences today announced its seed round of funding in the amount of $4.9 million led by True Ventures, with participation from Wireframe Ventures, Village Global and angel investor Chris Gibson (co-founder and CEO of Recursion)....
Why we invested in Enveda
In the Spring of 2018, one of our LPs based in Salt Lake City introduced me to a founder named Dan Wee from the vibrant bioscience community there. I enjoyed getting to know Dan and the business he was building...
In the Spring of 2018, one of our LPs based in Salt Lake City introduced me to a founder named Dan Wee from the vibrant bioscience community there. I enjoyed getting to know Dan and the business he was building...
Bioactivity-Based Molecular Networking for the Discovery of Drug Leads in Natural Product Bioassay-Guided Fractionation
It is a common problem in natural product therapeutic lead discovery programs that despite good bioassay results in the initial extract, the active compound(s) may not be isolated during subsequent bioassay-guided purification.....
It is a common problem in natural product therapeutic lead discovery programs that despite good bioassay results in the initial extract, the active compound(s) may not be isolated during subsequent bioassay-guided purification.....
Mass spectrometry searches using MASST
Introduced in 1990, a tool for discovering related protein or gene sequences named Basic Local Alignment Search Tool (BLAST) enabled researchers to query ....
Introduced in 1990, a tool for discovering related protein or gene sequences named Basic Local Alignment Search Tool (BLAST) enabled researchers to query ....
Global chemical effects of the microbiome include new bile-acid conjugations
A mosaic of cross-phylum chemical interactions occurs between all metazoans and their microbiomes....
A mosaic of cross-phylum chemical interactions occurs between all metazoans and their microbiomes....
Celebrating the departure of an outstanding employee
A few weeks ago, Viswa Colluru, a Senior Product Manager at Recursion, scheduled time with me to share that he would be leaving Recursion....
A few weeks ago, Viswa Colluru, a Senior Product Manager at Recursion, scheduled time with me to share that he would be leaving Recursion....
Blogs
MACHINE LEARNING WILL REVOLUTIONIZE METABOLOMICS
by David Healey
We are at a junction where improvements in mass spectrometry equipment and computational workflows have enabled large amounts of data to be collected...
by David Healey
We are at a junction where improvements in mass spectrometry equipment and computational workflows have enabled large amounts of data to be collected...
Fulfilling the Promise of Natural Products with Technology: Discovering the Next Generation of Small Molecules
by Matt Healy
“In twenty years of Big Pharma experience, I have seen both the promise of small-molecule Drug Discovery (helping take four molecules all the way from Lead Discovery through Preclinical Development...
by Matt Healy
“In twenty years of Big Pharma experience, I have seen both the promise of small-molecule Drug Discovery (helping take four molecules all the way from Lead Discovery through Preclinical Development...
Drug Discovery Productivity at Enveda —Biotech Innovation with Big Pharma Efficiency
by Bryan Norman
“Most drug discovery projects follow a standard life cycle (left). Any slow step will slow down the entire process, resulting in drug discovery productivity losses. Efficiency gains must address the rate-limiting steps...
by Bryan Norman
“Most drug discovery projects follow a standard life cycle (left). Any slow step will slow down the entire process, resulting in drug discovery productivity losses. Efficiency gains must address the rate-limiting steps...
ARTEMISININS, MALARIA, AND THE QUEST TO SYSTEMATIZE COLLABORATION BETWEEN NATURE AND SCIENTISTS (CURES AND NOBEL PRIZES)
by Bryan Norman
“Over 3,500 year ago, ancient Sumarians and Egyptians chewed willow bark to relieve pain and fever. Today, aspirin is the most widely used drug on the planet.”...
by Bryan Norman
“Over 3,500 year ago, ancient Sumarians and Egyptians chewed willow bark to relieve pain and fever. Today, aspirin is the most widely used drug on the planet.”...
Trends & Insights
Subscribe to our newsletter and follow us on social.